- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02233296
Food-Effect Study in Healthy Participants
April 3, 2018 updated by: Eli Lilly and Company
A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects
This study will evaluate the effect of food on the pharmacokinetics (PK) of a single dose of lasmiditan in healthy participants.
Study Overview
Detailed Description
An open-label, cross-over, two-period, randomized, sequential study in order to investigate the effect of food on the pharmacokinetics of lasmiditan 200 mg.
Two single doses of lasmiditan will be administered with the participants in fed and fasted states.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female aged 18-50 years.
- Able and willing to give written informed consent.
- Females of child bearing potential must be using or willing to use a medically acceptable method (as defined by the Investigator) of birth control.
- Body mass index (BMI) within 19 and 29.9 kilograms per meter squared (kg/m²).
- No clinically significant abnormalities (as determined by the Principal Investigator) in hematology, blood chemistry and urinalysis lab tests at screening.
- No history of alcohol or drug abuse within the past year. Negative urinary drugs of abuse and alcohol screen determined within 21 days of the start of the study and at check-in Day -1.
- Must be able to understand the requirements of the study and must be willing to comply with the requirements of the study.
Exclusion Criteria:
- Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the participant unsuitable for the study.
- Pregnant or breast-feeding women.
- Use of any prescription within 14 days prior to dosing (except hormonal contraceptives) or over the-counter medications, including vitamins and herbal or dietary supplements within 7 days prior to dosing unless approved by the Investigator and Medical Monitor.
- History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol; a positive urine screen for drugs of abuse or alcohol.
- History of orthostatic hypotension with or without syncope.
- At imminent risk of suicide (positive response to question 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]) or had a suicide attempt within 6 months prior to screening.
- Participation in any clinical trial of an experimental drug or device in the previous 30 days.
- Positive Hepatitis C antibody, Hepatitis B surface antigen, or positive human immunodeficiency virus (HIV) antibody.
- Donated plasma in the 7 days or blood in the 3 months preceding study drug administration.
- Inability to communicate well with the Investigator and study staff (i.e., language problem, poor mental development or impaired cerebral function).
- Inability to fast or consume the food provided in the study.
- Relatives of, or staff directly reporting to, the Investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
|
2 discrete doses separated by 6 days.
Other Names:
|
Experimental: Group B
Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
|
2 discrete doses separated by 6 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics - Cmax (ng/mL)
Time Frame: Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
This study was designed to estimate the relative bioavailability of lasmiditan 200 mg in the fed state relative to the fasted state.
For each primary pharmacokinetic endpoint, i.e., Area under concentration curve (time zero to last, time zero to infinity), Maximum concentration, point estimates and corresponding 90% confidence intervals were constructed.
Duration of the study was approximately 5 weeks, including up to 3 weeks for screening and 16 days on study (2 - 3 day dosing periods, 6 day washout period and follow-up).
|
Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
Pharmacokinetics - Tmax (Hours)
Time Frame: Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
This study was designed to estimate the relative bioavailability of lasmiditan 200 mg in the fed state relative to the fasted state.
For each primary pharmacokinetic endpoint, i.e., Area under concentration curve (time zero to last, time zero to infinity), Maximum concentration, point estimates and corresponding 90% confidence intervals were constructed.
Duration of the study was approximately 5 weeks, including up to 3 weeks for screening and 16 days on study (2 - 3 day dosing periods, 6 day washout period and follow-up).
|
Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
Pharmacokinetics - AUC0-t (ng.h/mL)
Time Frame: Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
This study was designed to estimate the relative bioavailability of lasmiditan 200 mg in the fed state relative to the fasted state.
For each primary pharmacokinetic endpoint, i.e., Area under concentration curve (time zero to last, time zero to infinity), Maximum concentration, point estimates and corresponding 90% confidence intervals were constructed.
Duration of the study was approximately 5 weeks, including up to 3 weeks for screening and 16 days on study (2 - 3 day dosing periods, 6 day washout period and follow-up).
|
Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
Pharmacokinetics - AUC0-inf (ng.h/mL)
Time Frame: Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
This study was designed to estimate the relative bioavailability of lasmiditan 200 mg in the fed state relative to the fasted state.
For each primary pharmacokinetic endpoint, i.e., Area under concentration curve (time zero to last, time zero to infinity), Maximum concentration, point estimates and corresponding 90% confidence intervals were constructed.
Duration of the study was approximately 5 weeks, including up to 3 weeks for screening and 16 days on study (2 - 3 day dosing periods, 6 day washout period and follow-up).
|
Sequential timepoints on each dosing day pre-dose to 30 h (timepoints - pre-dose and then 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours post dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety. Safety Measurements Include Physical Exams, Vital Signs, ECGs, Clinical Laboratory Assessments, AEs, Columbia Suicide Severity Rating Scale (C-SSRS).
Time Frame: Duration of study- From Screening (signing informed consent form) to End-of-Study ~ 15 days
|
Safety was evaluated in all participants (n=30) under the fasted condition and the fed condition, not by sequence of assigned cross-over (fed/fasted or fasted/fed).
The number of unique subjects with an AE and the number of events are provided.
|
Duration of study- From Screening (signing informed consent form) to End-of-Study ~ 15 days
|
Tolerability
Time Frame: 15 days
|
Tolerability was defined as the number of participants that did not withdraw from the study early due to adverse events.
|
15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
February 1, 2015
Study Completion (Actual)
March 1, 2015
Study Registration Dates
First Submitted
August 28, 2014
First Submitted That Met QC Criteria
September 2, 2014
First Posted (Estimate)
September 8, 2014
Study Record Updates
Last Update Posted (Actual)
April 5, 2018
Last Update Submitted That Met QC Criteria
April 3, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16905
- H8H-CD-LAHR (Other Identifier: Eli Lilly and Company)
- COL MIG-104 (Other Identifier: CoLucid Pharmaceuticals)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Lasmiditan
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedMigraine With or Without AuraUnited States
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedAcute MigraineUnited States
-
IlDong Pharmaceutical Co LtdCompletedAcute MigraineKorea, Republic of
-
Eli Lilly and CompanyAlgorithme Pharma Inc; CoLucid PharmaceuticalsCompletedMigraineUnited States, Canada
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompleted
-
Hospital Clínico Universitario de ValladolidRecruitingMigraine | Migraine Disorders | Headache Disorders | Migraine With AuraSpain
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCoLucid Pharmaceuticals; SNBL Clinical Pharmacology Center, Inc.Completed
-
Eli Lilly and CompanyCompletedHealthyUnited States
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedAn Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR)Migraine DisordersUnited States, United Kingdom, Germany